Immix Biopharma, Inc.
IMMX
$1.96
-$0.07-3.45%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -21.61M | -21.89M | -19.02M | -18.21M | -15.43M |
| Total Depreciation and Amortization | 115.40K | 77.20K | 52.70K | 28.90K | 5.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.94M | 3.21M | 3.16M | 2.96M | 2.40M |
| Change in Net Operating Assets | 3.97M | 2.80M | 967.30K | 2.11M | 1.65M |
| Cash from Operations | -14.60M | -15.80M | -14.85M | -13.11M | -11.37M |
| Capital Expenditure | -1.18M | -683.70K | -451.10K | -354.00K | -52.10K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1.18M | -683.70K | -451.10K | -354.00K | -52.10K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 15.95M | 16.54M | 26.66M | 31.37M | 15.52M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | -58.80K | -74.60K | -59.60K |
| Cash from Financing | 15.95M | 16.54M | 26.60M | 31.29M | 15.46M |
| Foreign Exchange rate Adjustments | -3.60K | 52.80K | 18.00K | 23.20K | 33.00K |
| Miscellaneous Cash Flow Adjustments | 0.00 | -- | -- | -- | -- |
| Net Change in Cash | 172.10K | 108.00K | 11.32M | 17.86M | 4.07M |